key: cord-0818963-xn6l30f8
authors: Fitouchi, Simon; Heger, Bob; Kremer, Laurent; Kremer, Stéphane; Ohlmann, Patrick
title: A case of acute disseminate encephalomyelitis after SARS-CoV-2 related acute respiratory distress syndrome
date: 2020-11-18
journal: J Neuroradiol
DOI: 10.1016/j.neurad.2020.11.001
sha: cbd90111e10374bba8df59fe6a62f19be9e03999
doc_id: 818963
cord_uid: xn6l30f8

nan

Reverse transcriptase-polymerase chain reaction in nasopharyngeal swab specimens was positive for SARS-CoV-2. The patient was intubated, sedated with midazolam and sufentanil, treated with empirical antibiotherapy (Cefotaxime, Spiramycine) and admitted to ICU. ARDS evolution was favorable, allowing a progressive withdrawal of respiratory support 14 days after ICU admission. Later, a tracheostomy was necessary because of impaired consciousness.

Although the sedation was stopped after ten days, the patient did not show signs of waking.

Neurological examination revealed no voluntary motor activity or eye-tracking, and only a spontaneous eye-opening. Focal neurologic signs and osteo-tendinous reflexes were absent.

Pupils were isocore and reactive to light. His Glasgow Coma scale was 5 out of 11 (vocal function is impossible through tracheostomia) and the Full Outline of UnResponsiveness 

Neurological damage is often observed in patients with ARDS due to COVID-19. 1 It has been previously shown that coronaviruses are able to induce direct central nervous system infections, as well as para-infectious disorders such as acute disseminated encephalomyelitis. 2,3 ADEM is a monophasic inflammatory demyelinating disorder of the CNS that occurs from a few days to weeks after a viral disease or a vaccination. It is mainly a pediatric disease, though it has also been reported in the adult population. 4 Treatment for ADEM is based on high dose corticosteroids, intravenous immunoglobulins Corticosteroids should be used with caution as evidence from coronavirus outbreaks suggests that they may prolong viral shedding. 5, 6 In cases of insufficient response or contraindications to corticosteroids, the second-line treatment relies on IVIg or PLEX. Full recoveries in pediatric populations have been described, however the use of IVIg is correlated with a risk of thromboembolism, which is itself considerably increased in patients with COVID-19. 7, 8 Third-line therapies are based on the administration of cyclophosphamide or rituximab. At present, we do not have definite therapeutic options and recovery times in this population.

However, we should be aware that patients with cerebral damage require prolonged stays in the ICUs which are already overburdened due to the current COVID-19 pandemic.

The authors have no conflicts of interest in relation to the findings reported in this article. 

Neurologic Features in Severe SARS-CoV-2 Infection

Human Coronavirus OC43 Associated with Fatal Encephalitis

Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV)

Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients

Acute disseminated encephalomyelitis: a longterm follow-up study of 84 pediatric patients

Early high-dose intravenous methylprednisolone in acute disseminated encephalomyelitis: a successful recovery

Adverse effects of human immunoglobulin therapy

Demyelinative brainstem encephalitis responsive to intravenous immunoglobulin therapy